Barriers to utilizing long-acting injectable antipsychotic medications

Annals of Clinical Psychiatry

Volumn 26, Issue 1, 2014, Pages 33-38

  Getzen, Hayley ^a   Beasley, Marie ^b   D'Mello, Dale A ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Michigan State University   (United States)

Author keywords

Antipsychotics; Barriers; Injectable; Long acting

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; LONG ACTING INJECTABLE ANTIPSYCHOTIC; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG FORMULARY; DRUG PREFERENCE; DRUG UTILIZATION; HEALTH SURVEY; HUMAN; INSURANCE; INTERNET; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PSYCHIATRIST; SCHIZOPHRENIA; TREATMENT OUTCOME; ADULT; CLINICAL PRACTICE; DELAYED RELEASE FORMULATION; ECONOMICS; HEALTH INSURANCE; INJECTION; MENTAL HEALTH SERVICE; PSYCHIATRY; STANDARD; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; INSURANCE, HEALTH; MENTAL HEALTH SERVICES; MICHIGAN; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRY;

EID: 84904550709     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rossell SL, Coakes J, Shapleske J, et al. Insight: its relationship with cognitive function, brain volume and symptoms in schizophrenia. Psychol Med. 2003; 33:111-119.
2. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51:826-836.
3. Smith TE, Hull JW, Israel LM, et al. Insight, symp-toms, and neurocognition in schizophrenia and schizoaf-fective disorder. Schizophr Bull. 2000;26:193-200.
4. Andreasen NC, Liu D, Ziebell S, et al. Relapse dura-tion, treatment intensity, and brain tissue loss in schizo-phrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170:609-615.
5. Rossler W, Salize HJ, van Os J, et al. Size of bur-den of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15:399-409.
6. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
7. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizo-phrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
8. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry. 2009;195:S13-S19.
9. Kane JM, Garcia-Ribera C. Clinical guideline recom-mendations for antipsychotic long-acting injections. Br J Psychiatry. 2009;195:S63-S67.
10. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
11. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2001;3:9-14.
12. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizo-phrenia. N Engl J Med. 2011;364:842-851.
13. Johnson DA. Historical perspective on antipsy-chotic long-acting injections. Br J Psychiatry Suppl. 2009;195:S7-S12.
14. Burns T. Knowledge about antipsychotic long-act-ing injections: bridging that gap. Br J Psychiatry Suppl. 2009;195:S5-S6.
15. Morrissette DA, Stahl SM. Optimizing outcomes in schizophrenia: long-acting depots and long-term treat-ment. CNS Spectr. 2012;17:10-21.
16. Patel MX, Nikolaou V, David AS. Psychiatrists' atti-tudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003;33:83-89.
17. Weiden PJ, Schooler NR, Weedon JC, et al. A random-ized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia: initial adherence outcome. J Clin Psychiatry. 2010;70:1397-1406.
18. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia: a critical system-atic review and meta-analysis of randomized long-term trials. Schizophr Res. 2011;127:83-92.
19. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and ris-peridone oral tablets. Eur Neuropsychopharmacol. 2005;15:111-117.
20. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68:1218-1225.
21. Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299.
22. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175:58-62.
23. Altamura AC, Aguglia E, Bassi M, et al. Rethinking the role of long-acting atypical antipsychotics in the commu-nity setting. Int Clin Psychopharmacol. 2012;27:336-349.
24. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260-267.